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PARDIOVASCULAR GENOMIC MEDICINE
See Introduction in the Inside This Issue section on page A-36)
rospects for Personalized Cardiovascular Medicine
he Impact of Genomics
eoffrey S. Ginsburg, MD, PHD, FACC,*†‡ Mark P. Donahue, MD, MHS,*†
. Kristin Newby, MD, MHS, FACC*†
urham, North Carolina
Sequencing of the human genome has ushered in prospects for individualizing cardiovascular
health care. There is growing evidence that the practice of cardiovascular medicine might
soon have a new toolbox to predict and treat disease more effectively. The Human Genome
Project has spawned several important “omic” technologies that allow “whole genome”
interrogation of sequence variation (re-sequencing, genotyping, comparative genome hybrid-
ization), transcription (expression profiling, tissue arrays), proteins (gas or liquid chromatog-
raphy and tandem mass spectroscopy [MS]), and metabolites (MS or nuclear magnetic
resonance profiling); deoxyribonucleic acid, ribonucleic acid, protein, and metabolic ap-
proaches all provide more exacting detail of cardiovascular disease mechanisms and, in some
cases, are redefining its taxonomy. Pharmacogenomic approaches are emerging across broad
classes of cardiovascular therapeutics to assist practitioners in making more precise decisions
about which drugs to give to which patients to optimize the benefit-to-risk ratio. Molecular
imaging is developing chemical and biological probes that can sense molecular pathway
mechanisms that will allow us to monitor health and disease. Together, these tools will enable
a paradigm shift from genetic medicine—on the basis of the study of individual inherited
characteristics, most often single genes—to genomic medicine, which by its nature is
comprehensive and focuses on the functions and interactions of multiple genes and gene
products, among themselves and with their environment. The information gained from such
analyses, in combination with clinical data, is now allowing us to assess individual risks and
guide clinical management and decision-making, all of which form the basis for cardiovas-
cular genomic medicine. (J Am Coll Cardiol 2005;46:1615–27) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.075College of Cardiology Foundation
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poday, large-scale sequencing and the ability to measure
enotypes at thousands of loci can generate an individual-
zed profile of health and/or disease. Deoxyribonucleic acid
DNA) microarrays, which generate a “molecular signature”
efining a particular phenotype, are another approach whose
ower resides in its ability to measure expression levels of
housands of genes in parallel (1,2). Genomic complexity is
lso reflected in proteomics—the analysis of the entire
rotein content of a cell or tissue—another approach that
ill be essential to bringing personalized health care to
ruition (3,4). At the end of the biochemical pathway lies
etabolomics, a breakthrough technology that allows visu-
lization of the biological complexity of small molecule
etabolites on a large scale in serum or other biological
uids (Table 1).
Linkage of genomic information with clinical data will
esult in predictive biosignatures (5) (Fig. 1) for use in
dentifying individuals predisposed to illness, classifying
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ccepted June 30, 2005.isease on a molecular basis to improve diagnostic and
rognostic precision, developing predictive pharmaco-
enomics profiles, and developing non-invasive methods to
etect disease and monitor response to therapy (6,7). As it
ecomes increasingly available, genomic medicine will result
n a significant paradigm shift from acute intervention to
rospective and personalized cardiovascular health care
Table 2). In this review, we highlight emerging knowledge
nd paradigms from a number of these technologies. Most
ad their genesis in genomic research; all are harbingers of
he potential for personalized cardiovascular care.
NA: GENOMICS AND SUSCEPTIBILITY TO
ASCULAR DISEASE
or the first time in history, health and disease can be
efined by genetic fingerprints enabled by the availability of
he entire complement of the human genome. An approx-
mate 0.1% difference in the nucleotide sequence of the
pproximately 22,500 genes in the human genome distin-
uishes individuals, often in the form of variations of a
ingle base pair called single nucleotide polymorphisms
SNPs) that are expected to be key in diagnostics and
resymptomatic testing. In complex phenotypes of poly-
enic origin such as cardiovascular disease (CVD), SNPs
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Personalized Cardiovascular Medicine November 1, 2005:1615–27rom multiple unlinked genes with weaker effects might be
nalyzed in parallel and used to generate quantitative risk
ssessments. The challenge remains to translate these dif-
erences into practical knowledge that will assist clinicians
nd improve patient outcomes. The promise for doing so
tems from recent advances in technology, including high-
hroughput genotyping as well as lower costs and improved
linical study designs. In addition, investigators are now
outinely banking DNA from large, well-phenotyped fam-
lies with inherited disorders as well as from disease cohorts
n anticipation of using large-scale genomic analyses to
etermine the gene(s) responsible for the observed traits.
Two major approaches are used to identify potential
enes for further analysis (8). The first approach, linkage
nalysis via whole genome scans, is an unbiased approach in
hich no prior assumptions are made about which genes are
ausal. The second is association studies, using the “candi-
ate gene” approach, in which knowledge of disease patho-
hysiology is used to develop hypotheses about the associ-
tion of variants in a specific gene or group of genes with
isease.
inkage analysis via genome-wide scanning in fami-
ies. To date, there are eight genome-wide linkage studies
hat have isolated candidate regions for coronary artery
isease (CAD) or myocardial infarction (MI) (9–16) (Table
able 1. The Genomic Medicine Toolbox
Dataset
(“Omic” Approach) Technology Platform or Approach
uman genome sequence
(genomics)
Single nucleotide polymorphisms
(estimated 10,000,000)
ene expression profiles
(transcriptomics)
Microarrays of 20,000 gene transcripts
roteome (proteomics) Protein arrays of specific protein
products (100,000)
etabolome (metabolomics) Metabolic profiles (1,000 to 10,000
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACS  acute coronary syndromes
BNP  brain natriuretic peptide
CAD  coronary artery disease
CI  confidence interval
CK  creatine kinase
CVD  cardiovascular disease
FLAP  5-lipoxygenase accessory protein
hs-CRP  high-sensitivity C-reactive protein
LQT  long QT
MEF2A  member of the myocyte enhancer factor 2
transcription factor family
MI  myocardial infarction
MS  mass spectroscopy
NMR  nuclear magnetic resonance
PUFA  polyunsaturated fatty acid
RR  relative risk
SNP  single nucleotide polymorphismtmetabolites)). Identification of the first autosomal dominant gene for
AD and MI was reported within the past year (16). A
eletion mutation in a member of the myocyte enhancer
actor 2 transcription factor family (MEF2A) was discov-
red in a genome-wide analysis of a single large family in
hich 13 members had CAD, nine of whom had MI.
e-sequencing of MEF2A in cases with CAD and MI
evealed three novel point mutations in exon 7 resulting in
mino acid substitutions (17). No mutations were observed
n the control population, but these novel mutations were
resent in nearly 2% of cases. Although these associations
re compelling, further determination of the prevalence and
linical significance of these mutations are needed.
Using a linkage-based study, investigators from Iceland
apped another gene predisposing to MI to a region of
hromosome 13 (15). The Icelandic population is particu-
arly well suited for these studies, owing to its homogeneity,
ow incidence of migration, and infrastructure to support
ollection of health data and DNA on a nationwide scale. A
arge-scale case-control association study subsequently im-
licated a 4-SNP haplotype of the gene ALOX5AP in MI.
he protein product of this gene, 5-lipoxygenase accessory
rotein (FLAP), operates in concert with 5-lipoxygenase in
eukotriene biosynthesis (18). 5-lipoxygenase was initially
ound to contribute to atherosclerosis sensitivity in mice and
ater implicated in human atherosclerosis (19,20). In the
os Angeles Atherosclerosis study, individuals homozygous
or the gene variant had heavier burdens of atherosclerosis
y carotid artery intima-media thickness (21). In addi-
ion, the observed genetic effect was more pronounced
mong those with a diet more concentrated in n-6
olyunsaturated fatty acids (5-lipoxygenase’s substrate in
eukotriene metabolism).
Appropriate validation studies will be required to support
he widespread use of any of these genes in routine testing,
ut as with the BRCA1 and BRCA2 variants in breast
ancer, MEF2A, FLAP, and 5-lipoxygenase gene variants
ight be the first of several clinically relevant genetic tools
o identify individuals at high risk for CAD and MI.
ssociation studies using the candidate gene approach.
everal genetic variants could be used as tools in clinical
ractice today. Factor V Leiden and Prothrombin G20210A
re examples of two such variants consistently associated
ith venous thrombosis, with adjusted odds ratios of ap-
roximately 3.0. On the basis of these data, a recommen-
ation for testing for these gene variants in certain cases of
enous thrombosis has been incorporated in several consen-
us panel guidelines (22,23).
In contrast, most gene variants are not as consistently
r strongly associated with arterial thrombosis and car-
iovascular clinical outcomes. Numerous small case-
ontrol association studies in selected populations have
dentified genes potentially predictive of CAD or MI, but
ften with low strengths of association or without ade-
uate adjustment for potential confounders. Frequently,
hese findings cannot be replicated in other populations.
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November 1, 2005:1615–27 Personalized Cardiovascular Medicineeta-analyses and large-scale association studies both
ttempt to address this issue and validate findings from
hese smaller studies—the latter is preferable and, now,
ore feasible. The most compelling associations are
hose that not only are highly significant but also have a
lausible biological mechanism.
Meta-analyses that attempted to clarify the relationship of a
umber of genetic variants in candidate genes for CAD and
I are shown in Table 4. Publication bias against studies with
egative results might have profound effects on the results of
eta-analyses with a tendency to overestimate the true risk.
hat said, most meta-analyses reveal only modest associations
f genetic variants with clinical end points with odds ratios
1.5. Apolipoprotein E (24), methylene tetrahydrofolate
eductase (25), angiotensin-converting enzyme (ACE)
26,27), apolipoprotein B (28), plasminogen activator
nhibitor-1 (29–31), fibrinogen beta chain (29,32), and
itric oxide synthase (33–35) genes have all been associated
ith intermediate phenotypes (e.g., lipid levels) or coronary
vents and await validation in large population studies.
arge case-control association studies. The development
f high-throughput genotyping has enabled the study of
andidate genes in larger populations (Table 5). In the
igure 1. Clinico-genomic biosignatures to predict health, disease, and en
evelop patterns of information and models for disease prediction and dru
able 2. What Genomics Might Bring to Cardiovascular Medici
● Clinical use of genomic variation to predict health and disease in indivi
● Incorporation of the complex interplay of genes and the environment vi
industrial, or socioeconomic
● Integration of precise phenotypic data with equally precise genotypic da
● Development of state-of-the-art technologies that assess the activity of
● Utilization of genomic information to streamline drug development and
● Discussion of the ethical, legal, and policy issues raised by the integratio
● Fundamentally alter the way in which health care is delivered and practiced ieneQuest study (36), 72 SNPs were analyzed in a case-
ontrol design (352 cases and 418 controls) for association
ith premature MI. Among 50,000 genotypes generated,
total of 11 SNPs in nine genes were differentially associ-
ted with CAD or MI. Three members of the throm-
ospondin family of proteins—matrix proteins putatively
nvolved in vascular integrity and calcium signaling—were
mong them. This study was later expanded to 210 SNPs in
n even larger-scale association study (36).
A second large-scale association study investigated
175,000 individual SNPs (37). A total of 112 polymor-
hisms in 71 candidate genes were identified from a screening
opulation and then confirmed in a second, larger popula-
ion. Among male subjects, the gap junction protein,
onnexin 37 (relative risk [RR] 1.4, 95% confidence interval
CI] 1.1 to 1.6) and the NAD(P)H component p22(phox)
RR 0.7, 95% CI 0.6 to 0.9) were associated with MI.
reviously, connexin 37 was identified as a prognostic
ndicator of plaque development (38), was associated with
resence of CAD (39), and was demonstrated to be differ-
ntially expressed in plaques from animal models of CAD
40). As a component of the NAD(P)H redox system,
22(phox) might play a role in the development of athero-
ental/drug response. Data from a variety of sources will be integrated to
ponse (5). SNPs  single nucleotide polymorphisms.
communities, and whole populations
s patient care, whether that environment be cellular,
a comprehensive and computationally robust clinical framework
portions of the genome, transcriptome, proteome, and metabolome
ove our understanding of drug safety, tolerance, and efficacy
the genome sciences into the practice of medicinene
duals,
s-à-vi
ta in
large
impr
n ofn order to optimize care and reduce costs overall
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Personalized Cardiovascular Medicine November 1, 2005:1615–27clerosis (41). A variant in p22(phox) has been associated
ith progression of CAD (42). Two different genes, plas-
inogen activation inhibitor-1 and stromelysin-1, were
ssociated with MI in female subjects. Stromelysin-1 was
ery strongly associated with MI (RR 4.7, 95% CI 2.0 to
2.2) and is a member of the matrix metalloproteinase
amily (matrix metalloproteinase-3) of enzymes implicated
n plaque pathophysiology (43).
In a third study, a multilocus approach in which groups
f SNPs from the same gene were simultaneously inves-
igated for an association with MI, single variants of
lpha-adducin (RR 0.73, 95% CI 0.59 to 0.91) and
holesteryl ester transfer protein (RR 0.82, 95% CI 0.68
o 0.97) genes were associated with reduced risk of MI
44). In addition, haplotypes in paraoxonase and apoli-
oprotein C-III were associated with risk for MI (RR
.52, 95% CI 0.39 to 0.77 and RR 1.71, 95% CI 1.28 to
.14, respectively).
The Toll receptor family has been well characterized with
espect to innate immunity (45), and functional variation in
oll-like receptor 4 is associated with a poor host response to
epsis (46). Given the now-established connection between
nflammation and atherosclerosis, it is not surprising that
he toll-like receptor 4 gene variant was associated with a
ower risk of developing carotid atherosclerosis (RR 0.54,
5% CI 0.32 to 0.98) (47,48). Observations such as these
hould catalyze the next round of candidate gene studies and
roduce an entirely new list of potential risk-promoting as
ell as protective biomarkers for CAD and MI.
able 3. Genome-Wide Linkage Studies in Families With CAD
Genome Scans Outcome Number and Type of S
auser et al. (9) Premature CAD 438 families (1,168 indi
ang et al. (10) Premature MI 428 families (1,613 indi
ajukanta et al. (11) Premature CAD 156 families (364 indivi
rancke et al. (12) CAD 99 families (535 individ
roeckel et al. (13) Premature CAD 513 families (1,406 indi
arrup et al. (14) ACS 61 families (161 individ
elgadottir et al. (15) MI 296 families (2,454 indi
ang et al. (16) CAD or MI 1 family (25 individuals
19 available for genot
Association study conducted in conjunction with linkage study.
ACS  acute coronary syndrome; CAD  coronary artery disease; MI  myoca
able 4. Case-Control Association Studies: Meta-Analyses of Ca
Gene Risk Allele
polipoprotein E 4/4
ethylene tetrahydrofolate reductase C677T
ngiotensin-converting enzyme insertion/deletion DD
ngiotensin-converting enzyme insertion/deletion DD
polipoprotein B Ins/Del (DD)
polipoprotein B Gln451Lys (GG)
lasminogen activator inhibitor-1 4G/5G
ibrinogen beta-chain G-455A
ndothelial nitric oxide Glu298Asp
ndothelial nitric oxide Intron-4AD  coronary artery disease; CI  confidence interval; MI  myocardial infarction.enome-wide association. In genome-wide association
tudies, genetic variants or “markers” spaced evenly across
he genome are evaluated individually for association with a
isease. In one of the first such analyses, 65,000 different
NPs were analyzed in 94 cases with MI and 658 control
ubjects (49). Six million genotypes were generated, and
NPs identified as associated with MI were then typed in a
eparate case series. A significant association was observed
etween MI and a block of genes that included the
ymphotoxin-alpha gene. These associations were supported
y nearly identical associations when cases were compared
ith two different control groups (Table 5). The association
f the lymphotoxin-alpha gene with MI in humans is
athophysiologically plausible, because lymphotoxin-alpha
as implicated in atherosclerosis in animal models (50).
ariant SNPs were found to not only influence transcrip-
ional levels of the gene but also to be associated with elevated
evels of C-reactive protein (CRP) and to profoundly influ-
nce the induction of cellular adhesion molecules, including
ascular cell adhesion molecule (VCAM)-1 (51).
Data from meta-analyses, case-control studies, and
enome-wide association studies all describe genes associ-
ted with, at most, a modestly increased risk for CAD and
I. This observation is consistent with the general para-
igm that complex diseases have small contributions from
ultiple genes. No studies have yet investigated the associ-
tion of a multiplex panel of several genetic variants with the
isk for CAD or MI. Yet, it is likely that multiple genetic
arkers will be required to determine the risk of developing
I
cts Population Demographics Gene Isolated? Reference
ls) U.S. and Europe No 13
ls) U.S. No 14
Finland No 15
Northeastern India No 16
ls) Germany No 17
Australia No 18
ls) Iceland Yes* 19
)
U.S. Yes 21
nfarction.
ate Genes for CAD or MI
utcome
Comparative Risk
(95% CI)
Studies
(Cases/Controls) Reference
D 1.42 (1.26–1.61) 48 (15,492/32,965) 24
D or MI 1.21 (1.06–1.39) 72 (12,193/11,945) 25
D 1.16 (1.08–1.25) 18 (4,442/11,008) 26
I 1.21 (1.11–1.32) 19 (2,848/10,256) 27
D or MI 1.19 (1.05–1.35) 22 (6,007/5,609) 28
D or MI 1.32 (1.14–1.54) 15 (1,816/2,054) 28
I 1.20 (1.04–1.37) 10 (1,515/1,866) 29
I 0.68 (0.46–0.99) 4 (745/816) 29
D or MI 1.31 (1.13–1.51) 14 (6,036/6,106) 30
D or MI 1.34 (1.03–1.75) 16 (6,212/6,737) 30or M
ubje
vidua
vidua
duals)
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November 1, 2005:1615–27 Personalized Cardiovascular Medicineiseases such as atherosclerosis or MI, and studies now can
e carried out to develop these as clinically useful diagnos-
ics. At present, however, there are no data strong enough to
upport the use of tests for individual polymorphisms in
outine clinical practice to predict the presence or extent of
AD or to risk-stratify patients for MI.
NA: DEFINING MOLECULAR
HENOTYPES AND PATHWAYS
lthough study of gene variants and their associations with
isease is important, presence of gene variants does not
ecessarily specify that a disease phenotype will be observed
linically. Ribonucleic acid is an intermediate gene product
hat results from the transcription of DNA sequence. Whereas
NA is a fixed set of information, RNA is dynamic and
ight change in response to various intracellular and extra-
ellular stimuli and environmental factors (e.g., dietary,
tress, hormonal, growth factors, smoking) in both health
nd disease. It is now possible to interrogate the entire
xpressed genome of approximately 25,000 transcripts (the
ranscriptome) using microarrays (“gene chips”). The “ex-
ression pattern” or RNA profile might serve as an addi-
ional means to subcategorize disease and/or predict its
esponse to various therapies as well as to define groups of
enes associated with a clinical outcome. Furthermore, it is
oised to become a valuable tool for candidate gene discov-
able 5. Large Case-Control Association Studies of Candidate G
Study (Reference)
Population
Demographics Cases/Controls O
amada et al. (37) Japanese 1,784/1,974
(male cohort)
amada et al. (37) Japanese 590/704
(female cohort)
zaki et al. (49) Japanese 1,133/1,006
obin et al. (44) Caucasian; England 547/505
elgadottir et al.* (15) Caucasian; Iceland,
England
1,532/1,354
cCarthy et al. (36) Caucasian; U.S. 352/418 Prema
coro
Association study conducted in conjunction with linkage study.
CAD  coronary artery disease; MI  myocardial infarction.ry for use in DNA-based association studies (52) as well as vor identifying protein markers in cases where the protein
roduct of highly expressed transcripts are secreted or shed
nto serum.
Studies of RNA samples from cancers have been partic-
larly revealing of “gene signatures” that correlate with treat-
ent response and survival. In CVD, transcriptomes from
elevant target tissues (e.g., coronary arteries) are more
ifficult to access. Recently, transcriptional profiling of
therosclerotic material from human and mouse aortas
dentified potential genes and biological pathways involved
n the molecular pathophysiology of atherosclerotic devel-
pment and progression as well as robust gene expression
atterns that are highly predictive for lesion severity (53). In
ddition, several novel genes were identified that were not
reviously associated with atherogenesis. Although it is
nlikely that aortic material will be used clinically, it is
aluable because: 1) several expressed genes from aortic
issue might also be measured in serum; it might be possible
o develop enhanced diagnostic capabilities for atheroscle-
osis; 2) the genes identified in these expression signatures
ight also be used to identify SNPs for large-scale analyses;
nd 3) important new mechanisms of disease might be
evealed (54).
Expression profiling of RNA from explanted hearts and
ndomyocardial biopsies has also been used to subclassify
eart failure (55,56). Gene expression signatures were de-
for MI or Premature CAD
e
Genes Investigated and
Genotypes Generated
Genes With Significant
Associations
71 genes investigated ● Connexin 37
● p22 (phox)
175,000 genotypes
(total for both cohorts)
● Plasminogen activator inhibitor-1
● Stromelysin-1
13,738 genes investigated
6,000,000 genotypes
● Lymphotoxin-alpha
35 genes investigated ● Alpha-adducin
● Cholesteryl ester transfer protein
61,016 genotypes ● Paraoxonase1, 2
● Apolipoprotein C-III
*In combination with
linkage study
• 5-Lipoxygenase activating protein
(FLAP)
140,000 genotypes
disease
111 genes investigated
160,000 genotypes
● Apolipoprotein E
● Low density lipoprotein-related
protein-1
● Angiotensin-1 converting enzyme
● Methylene tetrahydrofolate
reductase
● Factor VII
● Selectin-P
● Fibrinogen beta
● Thrombopoetin
● Glycoprotein-1b alpha
● Interleukin-1 receptor antagonist
● Thrombospondin 2 and 4
● Plasminogen activator inhibitor-2enes
utcom
MI
MI
MI
MI
MI
ture
naryeloped that highlighted important mechanistic information
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Personalized Cardiovascular Medicine November 1, 2005:1615–27bout the underlying pathophysiology of ischemic cardio-
yopathy versus cardiomyopathy of infectious etiology.
ore recently, gene expression profiles were used to develop
rognostic indexes for patients with congestive heart failure
ndergoing left ventricular assist device placement. The
rofiles accurately predicted the etiology of cardiomyopathy
56), providing a good argument for including these assays
n studies aimed at developing prognostic indicators or
iomarkers of response to therapy. Expression signatures
rom cardiac tissue are also being investigated as predictors
f future arrhythmias in the post-bypass surgery setting or
ith automatic defibrillator implantation (57).
Expression profiling of RNA from blood mononuclear
ells might also serve as a proxy for diseased tissue. This
ould be a breakthrough use of the technology to develop
redictive markers where the diseased tissue is inaccessible
such as vascular tissue). This is also an appealing approach
or disease processes in which the monocyte might be a
articipant, as is the case in atherosclerosis and transplant
ejection. In one study, molecular signatures from peripheral
lood expression profiles correlated well with biopsy-proven
llograft rejection (58). If these results are validated in larger
tudies, it would pave the way for a blood-based screening
est instead of the more invasive endomyocardial biopsy.
ROTEINS: BIOMARKERS OF RISK IN
THEROSCLEROTIC CVD
n cardiology, there has been rapid escalation in the search
or and identification of circulating protein biomarkers for
se in establishing diagnosis, determining prognosis, and
electing treatment. We are now confronted with a perplex-
ng variety of biomarkers of process and risk, from devel-
pment of atherosclerosis to plaque instability and rupture,
o arterial thrombosis associated with ischemia and myocar-
ial necrosis. As demonstrated with the recent publication
f data from the INTERHEART study (59) showing
poB/ApoA1 ratio as a measure of lipid abnormalities as
trong predictor of MI, even our fundamental constructs
egarding biomarkers of risk for CAD events are being
ontinually reshaped. This and other recent examples high-
ight the burgeoning potential of incorporating new protein
iomarker assessments in risk stratification. Moreover, with
he advent of mass spectroscopy (MS) as a tool to compre-
ensively examine the proteome—the full complement of
roteins in serum—there will undoubtedly emerge many
ovel candidate markers for CVD risk.
roponins as the prototypical protein biomarker for
ersonalized medicine. Protein biomarkers of myocardial
ecrosis are perhaps the best example of the evolution from
iagnostic tool to prognostic instrument to utility in treat-
ent selection. Until the early 1990s, biomarkers of myo-
ardial necrosis, predominantly creatine kinase (CK) and its
yocardial-specific isoform, CK-MB, were used largely to
onfirm the diagnosis of MI. With the development of
ensitive and specific cardiac troponin assays, measurable oelease of these proteins became not only a marker of the
ccurrence of MI, but also a powerful risk stratification tool
or subsequent adverse clinical outcomes (60–62). In meta-
nalyses, the odds ratios for death or MI in patients with
levated troponin measurements relative to those without
anged from 2.5 to 4.9 and were independent of type of
roponin (I or T) measured (63,64). Not only do these
iomarkers identify patients at increased risk, they contrib-
te independent information to risk stratification in the
ontext of readily identifiable clinical characteristics (65);
owever, the potential of this protein biomarker was most
ully realized when the association between troponin eleva-
ion and benefit from potent antithrombotic and antiplatelet
herapies and invasive management in acute coronary syn-
romes (ACS) became evident (66–72). Furthermore, anal-
ses showed that for both glycoprotein IIb/IIIa inhibitors
nd the early invasive strategy, treatment benefit was max-
mal among the highest risk ACS patients (positive tro-
onins), regardless of gender, helping to explain observa-
ions of differences in response to these therapies among
ale and female subgroups in randomized clinical trials
73,74). Thus, troponins provide one of the first examples of
he potential for personalized treatment of CVD, providing
framework that focuses on directing use of effective but
xpensive therapies in ways that can potentially avoid
dverse effects to patients.
volution of protein biomarker testing for personalized
ardiovascular care. Despite the potential of troponin
esting as an agent for personalized treatment, its story also
ighlights one of the challenges facing the development of
rotein biomarker approaches to risk stratification and
isease management. Data on the use of troponins and most
rotein markers reflect population averages; thus, they are
ot a perfect tool for either risk stratification or guiding
reatment selection at the individual patient level. Even
mong troponin-negative patients, there are those at in-
reased risk for adverse events who might benefit from a
articular therapy if they could be identified. Conversely,
mong troponin-positive patients are individuals for whom
enefit from a given treatment might be less substantial or
ess certain (66,75). This conundrum fuels the exploration
or additional protein biomarkers to further risk-stratify
roponin-positive and -negative patients with CVD and
mprove the overall desired sensitivity and specificity.
Table 6 displays a partial list of protein biomarkers for
isease state and risk and the general pathophysiological
rocess with which they are associated. Included are poten-
ial markers of plaque rupture or ischemia, hemodynamic
tress, and biomarkers that reflect the role of inflammation
n the atherosclerotic process. At present, many are in early
tages of development (i.e., “emerging”), have not been
alidated in the clinical setting, lack a commercially avail-
ble, standardized, and validated assay for widespread use,
r lack data supporting their independent clinical utility in
uiding treatment and management decisions, whereas
thers that have these characteristics are “in clinical use.”
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November 1, 2005:1615–27 Personalized Cardiovascular Medicinenflammation. Since the landmark observations of Ross
76), the role of inflammation in development and progres-
ion of atherosclerosis has been increasingly recognized.
irculating markers of inflammation correlate with presence
f atherosclerotic disease and risk for clinical events in both
table subjects with and without known CAD and those
ith ACS (77–86), and several existing therapies are
ssociated with decreases in circulating markers of inflam-
ation (84,87–90). It is less clear, however, that measure-
ent of inflammatory markers are useful in targeting
reatment selection to specific groups of patients (77,91).
The potential for using markers of inflammation to both
ssess risk and guide therapy was first explored with high-
ensitivity C-reactive protein (hs-CRP) in a substudy of the
holesterol and Recurrent Events (CARE) trial of CAD
econdary prevention with statin therapy. Patients with
igher hs-CRP levels had more cardiovascular events than
hose without evidence of inflammation (92); pravastatin
se was associated with a reduction of hs-CRP (87), a
nding subsequently shown to be common among statins
92–95), and patients with greater evidence of inflammation
y hs-CRP had a greater relative treatment benefit. Similar
bservations were made in subanalyses of the Air Force/
exas Coronary Atherosclerosis Prevention Study (AF-
APS/TexCAPS) and in ACS patients in the Pravastatin
r Atorvastatin Evaluation and Infection Therapy-
hrombolysis In Myocardial Infarction 22 (PROVE IT-
IMI 22) study (89,96); in these studies, treatment benefit
able 6. Protein Biomarkers of Disease State and Risk:
n Clinical Use and Emerging
yocardial necrosis
Troponin I/T Clinical use
Creatine kinase-MB Clinical use
Myoglobin Clinical use
schemia
Unbound free fatty acids Emerging
Ischemia modified albumin Clinical use
Whole blood choline Emerging
B-type natriuretic peptide Clinical use
nflammation/plaque stability
C-reactive protein Clinical use
Interleukin-6 Emerging
Interleukin-10 Emerging
Interleukin-18 Emerging
Pregnancy-associated plasma protein-A Emerging
CD40 ligand Emerging
Myeloperoxidase Emerging
Placental growth factor Emerging
Vascular endothelial growth factor Emerging
Serum amyloid A Emerging
Monocyte chemoattractant protein-1 Emerging
Matrix metalloproteinases Emerging
Lipoprotein-associated phospholipase A2 Emerging
emodynamic stress
B-type natriuretic peptide Clinical use
N-terminal proB-type natriuretic peptide Clinical use
linical use  test available commercially and has demonstrated diagnostic
r prognostic utility in clinical studies; see text for references.as observed even in patients with lipid levels below rreatment guidelines. An ongoing randomized trial, Justifi-
ation for the Use of statins in Primary prevention: an
nternational Trial Evaluating Rosuvastatin (JUPITER), is
esting the hypothesis that patients with low-density li-
oprotein cholesterol below current treatment guidelines,
ut with evidence of inflammation on the basis of elevated
s-CRP, might benefit from statin therapy directed primar-
ly at reducing inflammation (97).
Recent reports of the association of myeloperoxidase, pla-
ental growth factor, pregnancy-associated plasma protein-A
PAPP-A), CD40 ligand, interleukin-6, interleukin-10,
onocyte chemoattractant protein-1, and other inflammatory
arkers, including hs-CRP, with risk and in some cases,
reatment effect, in ACS highlight the growing recognition of
he critical importance of inflammation in CVD (98–111).
hether specific therapies directed at specific components of
he inflammatory process or targeted more generally at reduc-
ng inflammation will confer improved outcomes remains to be
roved.
emodynamic stress. Brain (or B-type) natriuretic pep-
ide (BNP), a neurohormone produced in increasing
mounts by ventricular myocardium in response to dilata-
ion and pressure overload, has proved useful in diagnosis
nd risk stratification of heart failure patients. Particular
enefits have come in the emergency room when the cause
f dyspnea was unclear (112–114). Brain natriuretic peptide
nd immunoreactive amino-terminal pro-brain natriuretic
eptide also appear to have utility in risk stratification of
symptomatic individuals without known CVD, those with
table CAD and those post-ACS (115–119). They might
lso rapidly detect ischemia in the absence of infarction
120), but their role in guiding clinical management is less
lear. In one study, BNP predicted sudden cardiac death
fter MI, even in patients with ejection fractions 30%
121). Although this finding must be substantiated, it
uggests that BNP could potentially be used to determine
hich non-Multicenter Automatic Defibrillator Implanta-
ion Trial (MADIT) II patients might benefit from a
efibrillator. In Treat Angina with Aggrestat and determine
ost of Therapy with an Invasive or Conservative Strategy–
hrombolysis In Myocardial Infarction (TACTICS-TIMI)
8, a randomized study of early invasive management
ompared with conservative care of ACS patients, BNP
evels identified patients at increased risk for mortality but
id not differentiate patients more likely to benefit from
arly invasive management (122). Thus, as with markers of
nflammation, additional work remains to establish these
arkers as fundamental components of personalized cardio-
ascular care.
ultimarker strategies: a forerunner to clinical proteom-
cs. Incremental information might be obtained by simul-
aneously measuring biomarkers of varying types or subtypes
n determining prognosis for a particular population. Several
ultimarker strategies have been published, ranging from
sing a multimarker approach to improve MI diagnosis and
isk stratification in low-risk chest pain patients (123) to
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ynamic stress to enhance risk stratification in patients with
CS (65,107–110). In each example, the information pro-
ided by groups of markers was additive to conventional risk
ssessment tools such as electrocardiography or clinical
ariables such as age and renal function.
As we progress into the era of genomics and proteomics,
e increasingly will be presented with new putative biomar-
ers of disease state and risk not only from biomarker,
enetic, or RNA approaches but also from large-scale
roteomic strategies (124). The National Heart Lung and
lood Institute recently recognized (125), as the challenges
or the next decade: 1) development of systematic and
dequately-powered approaches to validate the associations
f protein biomarkers with disease state, risk, or treatment
ffect that are identified from genomic and proteomic
pproaches; and 2) development of informatics and analyt-
cal platforms for grouping putative markers of risk into
panels” that are clinically useful.
ETABOLOMICS: A SYSTEMS BIOLOGY APPROACH
O BIOMARKERS OF HEALTH AND DISEASE
etabolomics—the study of small molecule (non-protein)
rofiles in biological samples—resides at the end of the
iological road that starts with DNA (Table 1). We expect
hat metabolomics will be an integral part of the broader
pectrum of personalized medicine (Fig. 1). Efforts are
nderway in several centers to catalogue the complete
uman metabolome (estimated to contain approximately
,000 molecules) in both health and disease (126,127). The
oal of metabolomics is to relate physiological consequences
f disease (i.e., the metabolites associated with pathological
rocesses) to the genomic origins of those diseases. Metab-
lite profiles can provide insight into cellular physiology and
he environment in which that physiology takes place.
Although limited mammalian metabolomic data have
een amassed to date, there has been definite progress in
sing this approach to understand individual responses to
iet and therapies aimed at metabolic disorders (128–131).
n one study, the dietary effects of poly-unsaturated fatty
cids (PUFAs) were correlated with gene expression and
ipid metabolite level to understand the signaling pathways
nvolved in PUFA-mediated impact on human health
130). In another study, a therapeutic agent for diabetes and
besity, roziglitazone, was studied in a mouse model that
rovided many of the metabolic hallmarks found in humans
ith these conditions (elevated serum glucose, insulin, and
riglycerides) as the animals became obese on specific diets.
eceiving high doses of roziglitazone, the animals re-
ponded with changes to the three biomarkers. At the same
ime, the animals developed hepatic lipidosis, which could
nly be explained though quantitative fatty acid analysis of
ll lipid classes in liver, blood, and muscle (132). This type
f study might permit identification of subsets of patients
ho could benefit from specific (personalized) dietary in- uervention or nutritional supplementation for disease pro-
hylaxis. Lastly, 1H nuclear magnetic resonance (NMR)
lasma analyses appear to differentiate between patients
ith and without CAD and might provide non-invasive
ethods for following disease burden and activity (133).
ithout question, the most mature metabolomics applica-
ion is the use of biomarkers as diagnostics and indicators of
isease progression. Serum cholesterol measurement is the
est example of a limited form of metabolomics currently in
linical use. It provides proof-of-principle that one can
easure a metabolite and offer useful advice to a patient
therwise deemed healthy: it is truly prospective in nature
134).
The two principal methods of examining metabolites,
MR and MS, are well established and already standard in
ost hospitals. Nuclear magnetic resonance requires mini-
al sample processing, preserves sample integrity, and can
apidly identify and localize abundant analytes in a sample.
ass spectroscopy can quantify individual components
ithin a sample and allows simple spectral analysis when
oupled with a chromatograph. Newer time-of-flight MS
echnology has reduced analysis times to just a few minutes.
he challenge for metabolomics—as for proteomics—will
e to move to the realm of multiplex testing and high-
hroughput screening of hundreds or even thousands of
etabolites, just as microarrays are now used to examine the
ctivity of thousands of genes simultaneously.
HARMACOGENOMICS: SAFETY AND EFFICACY
N CARDIOVASCULAR THERAPIES
he field of pharmacogenomics—the use of genomic vari-
tion to predict efficacy and toxicity of drug therapy—might
e the most promising area for near-term clinical applica-
ion of genomic information. Commonly used medications
uch as lipid-lowering therapy, anti-hypertensives, anti-
rrhythmics, and anti-coagulants have differential effects on
he basis of individual genetic variation. No fewer than 40
harmacogenomic variants have been associated with drug
esponse (135). Ultimately, both prospective data and proof
f causality will be necessary to make clinical pharmacoge-
etic tests robust.
Recently, associations were found between lipid response
o 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reduc-
ase inhibitors and variants in the HMG-CoA reductase
ene (136) and a variant of the estrogen receptor and HDL
esponse in women on estrogen replacement (137). In
ypertension, variation in the alpha-adducin gene was
ssociated with renal sodium resorption and salt-sensitive
ypertension in animal models and humans (138,139). A
road initial study found no association with MI (140), but
focused follow-up study revealed a specific benefit (RR
.49, 95% CI 0.32 to 0.77) for those with the alpha-adducin
ariant (141). Thus, variation in this gene might identify
hich hypertensive patients would most benefit from di-
retic therapy.
m
b
A
i
t
i
(
b
g
a
t
p
g
t
a
e
I
D
o
w
t
s
o
w
t
t
a
c
u
i
s
c
t
c
L
t
g
b
s
w
o
m
m
t
a
i
l
r
(
w
u
o
s
“
p
“
b
T
s
m
t
g
F
g
o
m
d
M
C
O
T
i
p
t
i
a
t
m
q
g
e
b
s
a
p
u
p
a
l
p
(
r
m
v
u
t
t
p
c
p
p
a
1623JACC Vol. 46, No. 9, 2005 Ginsburg et al.
November 1, 2005:1615–27 Personalized Cardiovascular MedicineBeta-blockers and ACE inhibitors are standard treat-
ents for heart failure (142). Genetic variation in the
eta1-adrenergic receptor has been well characterized. The
rg389Gly polymorphism results in differential stimulation
n response to agonists; thus, it produces a different response
o blockade (143). Recently, an analysis of DNA from 1,040
ndividuals in the Beta-Blocker Evaluation of Survival Trial
BEST), in which there was no survival benefit with
ucindolol in the overall population, showed that homozy-
otes for the Arg389 variant had a 36% reduction in death
nd hospitalizations at two years (144). This study illustrates
he importance of collecting biological specimens to stratify
atients by genotype and the potential for genetic hetero-
eneity to confound the findings of randomized controlled
rials designed around traditional and imprecise clinical
ttributes.
Polymorphisms in the ACE pathway also provide an
xample of the possibility of pharmacogenomics in practice.
n a population of chronic heart failure patients, the ACE
D polymorphism was significantly associated with death
r need for transplant, but only those with ACE DD treated
ith beta-blockers had improved survival compared with
hose not on beta-blockers (145). In another study from the
ame group, patients with the DD polymorphism had worse
utcomes on low-dose ACE inhibitor therapy compared
ith high-dose (146). In addition, high-dose ACE inhibi-
ors and beta-blockers had the greatest association with
ransplant-free survival in those with the DD variant.
One area with great potential for pharmacogenomic
pplications is arrhythmias. The long QT syndrome (LQT)
auses sudden death and has traditionally been diagnosed
sing clinical criteria (147). Long QT syndromes are clin-
cally homogeneous but genetically heterogeneous, and
tudies over the last 10 years have yielded better molecular
haracterization of these disorders and subsequently better
argeted therapy (148). It is now known that LQT-1 is
aused by a potassium channel defect (KVLQT1 gene) and
QT-3 by a sodium channel defect (SCN5A); therefore,
he choice of therapeutic strategy is now dictated by
enotype. Long QT syndrome-1 responds better to beta-
lockers than LQT-3, which responds more favorably to
odium channel agents, such as flecanide, and might be
orsened by beta-blockers (149,150). It is likely that forms
f acquired LQT, such as those induced by medications,
ight have a similar molecular basis.
Variation in drug metabolism has implications for phar-
acogenomics. Two variations within the gene CYP2C9,
he principal enzyme that metabolizes warfarin, are associ-
ted with increased risk of over-anticoagulation and bleed-
ng events (151). The variations are common in the popu-
ation and accurately predict the mean warfarin dose
equired for a therapeutic international normalized ratio
INR). With such a clearly defined phenotype for a gene
ith common alleles, one could conceive of an algorithm for
se in anti-coagulation clinics to dose warfarin on the basis
f a patient’s CYP2C9 genotype. Validation of such a wtrategy could easily be accomplished in a clinical trial, with
time to therapeutic INR” and safety measures as key end
oints.
The holy grail of pharmacogenomics is to deliver the
right drug for the right patient” by accurately predicting
oth therapeutic response and safety before prescribing it.
o fulfill this promise, new “smart trials” are needed with
tratification of entry according to this new type of infor-
ation. When trials are not possible, appropriate registries
hat couple clinical and biological information can help
enerate this needed knowledge. The recent release of the
ood and Drug Administration’s guidance on pharmaco-
enomics (152) is a significant step toward the development
f personalized medicine and a statement of the U.S. govern-
ent’s official advocacy of this paradigm for the future of
rug development and health care.
OLECULAR IMAGING OF THE
ARDIOVASCULAR SYSTEM: THE CONVERGENCE
F GENOMICS AND ENGINEERING
he development of rationally designed chemical or biolog-
cal probes and imaging reporter agents that sense molecular
athway mechanisms now allow us to monitor the activity of
hose pathways in health and disease. Use of genomic
nformation and development of imaging systems in small
nimals is resulting in a rapid evolution of molecular imaging
o display and quantify molecular and cellular targets in vivo.
Optical coherence tomography (OCT) is being used to
easure the macrophage content of arterial plaques. These
uantitative measures might aid in determining prognosis and
uiding therapy (153). Radiolabeled antibodies against
pitopes on low-density lipoprotein such as I-125 MDA2 have
een used in animal models as a means of assessing disease
everity (154). Magnetic resonance imaging, fluorescence im-
ging, bioluminescence imaging, positron emission/single-
hoton emission computed tomography (PET/SPECT), and
ltrasound are techniques that take advantage of molecular
robes designed to image enzymes (e.g., cathepsins B,D,K,S,
nd MMPs), receptors (e.g., GPCRs, integrins), and endothe-
ial cells (e.g., E-selectin, VCAM) as well as the biological
rocesses of apoptosis (phosphatidylserine), angiogenesis
VCAM), and thrombosis (fibrin, thrombin) (155). Magnetic
esonance nanoparticles might be targeted directly to specific
olecular species such as fibrin or integrins, allowing the
isualization of clot formation and angiogenesis (156). Molec-
lar imaging is already being applied in cancer and inflamma-
ory diseases as well as atherosclerosis, heart failure, and
hrombosis to: 1) detect disease earlier, 2) monitor disease
rogression, and 3) monitor response to therapies (155).
Although many of these techniques remain in the pre-
linical evaluation stage, the prospects of imaging the
hysiology of plaques and identifying those with vulnerable
hysiology might soon be realized. Used as an adjunct to
natomic imaging and standard functional imaging, these
ill be powerful tools for identifying the highest-risk patients
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hem and the best means of monitoring their response.
ONCLUSIONS
paradigm shift is taking place in cardiovascular care,
riven by the capability to perform routine genomic analysis
f individuals. In principle, this will include susceptibility
creening, comprehensive expression analyses, proteomic
nd/or metabolomic testing, and probabilistic relation of
hose results to discrete clinical end points. Ideally, genomic
edicine will be predictive and seamlessly integrated into
atient care. In the coming years, we expect that the
ddition of genome-level testing and sophisticated analyses
f genomic and environmental risk will further refine
ndividualized approaches to care in CVD patients. Geno-
ics will become increasingly pervasive in cardiovascular
edicine. It is imperative that the cardiology community be
omfortable with and embraces it so that patients can realize
ts full potential.
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